Sagimet partner Ascletis enrolls 120 patients in Phase 3 trial of denifanstat for rGBM

Sagimet Biosciences Inc.

Ascletis completed enrollment of 120 patients in Phase 3 registration trial of denifanstat plus bevacizumab for recurrent glioblastoma.
Interim analysis of progression-free survival anticipated after sufficient events from the 120 subjects.
Sagimet expects FASCINATE-2 Phase 2b NASH biopsy results and Phase 1 hepatic impairment data in Q1 2024.
Denifanstat is an oral FASN inhibitor; Sagimet licensed China rights to Ascletis in January 2019.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.